24 September 2021 - Ontario is now providing coverage for Trikafta, the latest and most effective treatment option for cystic fibrosis to become available, under its publicly funded drug program to give patients more access to life changing treatments for cystic fibrosis.

In addition to the drugs Orkambi and Kalydeco, the first drugs in this class to treat cystic fibrosis and currently funded through the Ontario Drug Benefit program, Ontario is now also providing coverage for Trikafta, giving patients access to more options for treatment they need. 

Ontario patients aged 12 and up who do not meet the lung function criteria may work with their clinician to apply to the Exceptional Access Program to be considered for funding on a case by case basis.

Read Ontario Government press release